文献速递儿科与产科急症重症综合管理与镇静镇痛

产前糖皮质激素暴露时间短与极早产儿结局的关系

Short Duration of Antenatal Corticosteroid Exposure and Outcomes in Extremely Preterm Infants.
PubMed 文献 · JAMA Netw Open · 2025-02-03
一句话结论队列研究显示,极早产儿产前单剂倍他米松暴露至出生的时间每增加1小时,存活率及无严重并发症存活率均略有改善(aRR 1.01)。

该队列研究纳入2016年1月至2021年2月美国国立儿童健康与人类发展研究所新生儿研究网络中心的1806例22 0/7至27 6/7周极早产儿,其中475例未用倍他米松,1331例在出生前24小时内暴露于单剂倍他米松。单剂暴露者给药至出生中位间隔3.8小时(IQR 1.4-9.5)。调整混杂因素后,间隔时间与存活独立相关(每增加1小时aRR 1.01,95%CI 1.00-1.01;每增加6小时aRR 1.04,95%CI 1.01-1.07),与无严重新生儿并发症存活也独立相关(每增加1小时aRR 1.01,95%CI 1.01-1.02;每增加6小时aRR 1.09,95%CI 1.04-1.14)。作者认为,对于有即将早产风险的女性,即使产前倍他米松暴露时间很短,也与新生儿存活及无严重并发症存活改善相关。

要点

  • 极早产儿(22 0/7–27 6/7周)产前单剂倍他米松至出生间隔每增加1小时,存活aRR 1.01(95%CI 1.00-1.01),每增加6小时aRR 1.04(95%CI 1.01-1.07)。
  • 同一人群无严重新生儿并发症存活:每增加1小时aRR 1.01(95%CI 1.01-1.02),每增加6小时aRR 1.09(95%CI 1.04-1.14)。
  • 单剂倍他米松暴露者给药至出生中位间隔仅3.8小时(IQR 1.4-9.5),提示极短暴露窗口也可能与获益相关。
  • 研究排除了多剂倍他米松暴露、未接受重症监护及先天畸形患儿,结论仅适用于单剂暴露且接受重症监护的极早产儿。

适用人群与场景

  • 胎龄22 0/7至27 6/7周、2016年1月至2021年2月出生于美国国立儿童健康与人类发展研究所新生儿研究网络中心的极早产儿。
  • 排除:暴露于多剂产前倍他米松的婴儿、未接受重症监护的婴儿、有先天畸形的婴儿。

研究设计与关键结果

  • 研究类型:队列研究;纳入1806例极早产儿(928例[51.3%]为男孩),其中475例未用倍他米松,1331例出生前24小时内暴露于单剂倍他米松。
  • 单剂倍他米松暴露者给药至出生中位间隔3.8小时(IQR 1.4-9.5)。
  • 主要终点存活至出院:给药至出生间隔每增加1小时aRR 1.01(95%CI 1.00-1.01),每增加6小时aRR 1.04(95%CI 1.01-1.07)。
  • 次要终点无严重新生儿并发症存活:每增加1小时aRR 1.01(95%CI 1.01-1.02),每增加6小时aRR 1.09(95%CI 1.04-1.14)。
  • 分析采用广义线性模型,调整胎龄、婴儿性别、母亲种族、教育程度、小于胎龄儿、分娩方式、多胎、胎膜早破及出生中心。

证据类型、等级与局限

  • 证据类型:队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于有即将早产风险的女性,作者认为即使产前倍他米松暴露时间很短,也与新生儿存活及无严重并发症存活改善相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: When preterm delivery is imminent, it remains unclear whether the timing from administration of antenatal betamethasone to birth may reduce mortality and morbidity among extremely preterm infants.

OBJECTIVE: To evaluate the association of duration from exposure to first dose of antenatal betamethasone with outcomes among extremely preterm infants.

DESIGN, SETTING, AND PARTICIPANTS: This cohort study enrolled infants born at 22 0/7 to 27 6/7 weeks' gestation from January 2016 to February 2021 at National Institute of Child Health and Human Development Neonatal Research Network centers. Infants exposed to multiple doses of antenatal betamethasone, infants who did not receive intensive care, and infants with congenital anomalies were excluded. Data were analyzed from October 2021 to December 2024.

EXPOSURE: Time in hours from anenatal betamethasone administration to birth.

MAIN OUTCOMES AND MEASURES: The primary outcome was survival to discharge. Secondary outcomes included survival without major morbidity and composites of individual morbidities and death. The association of time from antenatal betamethasone administration to birth with neonatal survival and morbidity was assessed using generalized linear models, adjusting for gestational age, infant sex, maternal race, education, small for gestational age, mode of delivery, multiple birth, prolonged rupture of membranes, and center of birth.

RESULTS: Of 7464 infants born during the study period, 1806 infants (928 [51.3%] boys) were included in the cohort: 475 with no betamethasone and 1331 with exposure to a single dose of betamethasone within 24 hours before birth. The median (IQR) administration-to-birth interval for infants born after a single dose of betamethasone was 3.8 (1.4-9.5) hours. The administration-to-birth interval was independently associated with survival (adjusted relative risk [aRR] per 1-hour increase, 1.01 [95% CI, 1.00-1.01]; aRR per 6-hour increase, 1.04 [95% CI, 1.01-1.07]) and survival without severe neonatal morbidity (aRR per 1-hour increase, 1.01 [95% CI, 1.01-1.02]; aRR per 6-hour increase, 1.09 [95% CI, 1.04-1.14].

CONCLUSIONS AND RELEVANCE: In this cohort study, for women at risk of imminent preterm birth, even short duration of exposure to antenatal betamethasone was associated with improved neonatal survival and survival without severe neonatal morbidity.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Chawla S, Wyckoff MH, Lakshminrusimha S, et al. Short Duration of Antenatal Corticosteroid Exposure and Outcomes in Extremely Preterm Infants. JAMA Netw Open. 2025. PMID: 39982720. doi:10.1001/jamanetworkopen.2024.61312

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。